GC509 / AstraZeneca, Gracell - LARVOL DELTA

Gracell Biotechnologies Acquisition Completed (GlobeNewswire) - "Gracell Biotechnologies Inc...today announced the completion of its previously announced agreement to be acquired by AstraZeneca, in accordance with the terms and conditions of the Agreement and Plan of Merger, dated as of December 23, 2023 (the 'Merger Agreement'), by and among the Company, AstraZeneca Treasury Limited, a private limited company incorporated under the laws of England and Wales ('Parent'), and Grey Wolf Merger Sub ('Merger Sub'), an exempted company with limited liability incorporated under the laws of the Cayman Islands and a wholly owned subsidiary of Parent. The acquisition was structured as a merger of Merger Sub with and into the Company with the Company surviving the merger as a wholly owned subsidiary of Parent....The Company also announced today that it has requested that trading of the ADSs on the Nasdaq Global Select Market ('Nasdaq') be suspended as of February 22, 2024 (New York Time)."

M&A • Acute Lymphocytic Leukemia • Hematological Malignancies • Immunology • Leukemia • Lupus • Multiple Myeloma • Oncology • Solid Tumor • Systemic Lupus Erythematosus